Literature DB >> 20304029

Tyrosine phosphorylation of SHIP promotes its proteasomal degradation.

Jens Ruschmann1, Victor Ho, Frann Antignano, Etsushi Kuroda, Vivian Lam, Mariko Ibaraki, Kim Snyder, Connie Kim, Richard A Flavell, Toshiaki Kawakami, Laura Sly, Ali G Turhan, Gerald Krystal.   

Abstract

OBJECTIVE: The activity of the SH2-containing-phosphatidylinositol-5'-phosphatase (SHIP, also known as SHIP1), a critical hematopoietic-restricted negative regulator of the PI3 kinase (PI3K) pathway, is regulated in large part via its protein levels. We sought to determine the mechanism(s) involved in its downregulation by BCR-ABL and by interleukin (IL)-4.
MATERIALS AND METHODS: We used Ba/F3(p210-tetOFF) cells to study the downregulation of SHIP by BCR-ABL and bone marrow-derived macrophages to study SHIP's downregulation by IL-4.
RESULTS: We show herein that BCR-ABL downregulates SHIP, but not SHIP2 or PTEN, and this can be blocked with the Src kinase inhibitor PP2, which inhibits the tyrosine phosphorylation of SHIP, or with the proteasomal inhibitor MG-132. We also show, using anti-SHIP immunoprecipitates, that c-Cbl and Cbl-b are associated with SHIP and that BCR-ABL induces SHIP's polyubiquitination. This ubiquitination can be blocked with PP2, consistent with the tyrosine phosphorylation of SHIP acting as a signal for its ubiquitination. In bone marrow-derived macrophages, IL-4 also leads to the proteasomal degradation of SHIP but, unlike in Ba/F3(p210-tetOFF) cells, SHIP2 is also proteasomally degraded and the degradation of both inositol phosphatases can be prevented with PP2 or MG-132.
CONCLUSION: Our results suggest that SHIP protein levels can be reduced via BCR-ABL and/or Src family member-induced tyrosine phosphorylation of SHIP because this triggers its polyubiquitination and degradation within the proteasome. 2010 ISEH-Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304029     DOI: 10.1016/j.exphem.2010.03.010

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  12 in total

1.  Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP.

Authors:  Michelle M Collazo; Kim H T Paraiso; Mi-Young Park; Amy L Hazen; William G Kerr
Journal:  Eur J Immunol       Date:  2012-07       Impact factor: 5.532

2.  The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies.

Authors:  Patrick Ehm; Marcus M Nalaskowski; Torsten Wundenberg; Manfred Jücker
Journal:  Nucleus       Date:  2015-02-27       Impact factor: 4.197

3.  Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.

Authors:  J A Cutler; R Tahir; S K Sreenivasamurthy; C Mitchell; S Renuse; R S Nirujogi; A H Patil; M Heydarian; X Wong; X Wu; T-C Huang; M-S Kim; K L Reddy; A Pandey
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

4.  Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.

Authors:  Gwenny M Fuhler; Robert Brooks; Bonnie Toms; Sonia Iyer; Elizabeth A Gengo; Mi-Young Park; Matthew Gumbleton; Dennis R Viernes; John D Chisholm; William G Kerr
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 5.  Inhibitor and activator: dual functions for SHIP in immunity and cancer.

Authors:  William G Kerr
Journal:  Ann N Y Acad Sci       Date:  2010-12-13       Impact factor: 5.691

6.  SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.

Authors:  Shawn P Fessler; Naomi Rosenberg; Linda B Baughn
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

7.  Alternative activation of macrophages by IL-4 requires SHIP degradation.

Authors:  Shelley B Weisser; Keith W McLarren; Nicole Voglmaier; Christina J van Netten-Thomas; Andrey Antov; Richard A Flavell; Laura M Sly
Journal:  Eur J Immunol       Date:  2011-05-13       Impact factor: 5.532

8.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

Review 9.  Targeting SHIP1 and SHIP2 in Cancer.

Authors:  Chiara Pedicone; Shea T Meyer; John D Chisholm; William G Kerr
Journal:  Cancers (Basel)       Date:  2021-02-20       Impact factor: 6.639

10.  The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.

Authors:  Samantha D Pauls; Sandrine T Lafarge; Ivan Landego; Tingting Zhang; Aaron J Marshall
Journal:  Front Immunol       Date:  2012-08-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.